Semnur said the combined company, if the deal goes through, will operate as Semnur Pharmaceuticals with Scilex as the majority holder. It plans to seek approval from the SPAC's shareholders in the second half of 2024.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/DtiFn6P
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment